

RESEARCH ARTICLE

MPL36, a major plasminogen (PLG) receptor in pathogenic *Leptospira*, has an essential role during infection

Weinan Zhu¹[✉], Felipe J. Passalia^{1,2}[✉], Camila Hamond^{1,3}[✉], Cecília M. Abe³, Albert I. Ko^{1,4}, Angela S. Barbosa³, Elsie A. Wunder, Jr.^{1,4*}

1 Department of Epidemiology of Microbial Diseases, Yale School of Public Health, New Haven, Connecticut, United States of America, **2** Laboratory of Vaccine Development, Instituto Butantan, São Paulo, Brazil, **3** Laboratory of Bacteriology, Instituto Butantan, São Paulo, Brazil, **4** Gonçalo Moniz Institute, Oswaldo Cruz Foundation; Brazilian Ministry of Health; Salvador, Brazil

 These authors contributed equally to this work.

[✉]a Current address: Department of Laboratory Medicine, Xin Hua Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China

[✉]b Current address: National Veterinary Services Laboratories, Animal and Plant Health Inspection Service (APHIS), U.S. Department of Agriculture, Ames, Iowa, United States of America

* elsio.wunder@yale.edu



 OPEN ACCESS

Citation: Zhu W, Passalia FJ, Hamond C, Abe CM, Ko AI, Barbosa AS, et al. (2023) MPL36, a major plasminogen (PLG) receptor in pathogenic *Leptospira*, has an essential role during infection. PLoS Pathog 19(7): e1011313. <https://doi.org/10.1371/journal.ppat.1011313>

Editor: D. Scott Samuels, University of Montana, UNITED STATES

Received: March 23, 2023

Accepted: July 10, 2023

Published: July 24, 2023

Copyright: © 2023 Zhu et al. This is an open access article distributed under the terms of the [Creative Commons Attribution License](https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Data Availability Statement: All relevant data are within the manuscript and its [supporting information](#) files.

Funding: This work was supported by NIH grants U01AI088752 and R01AI121207 (AIK), and R21AI163663 (EAWJ), FAPESP (Fundação de Amparo à Pesquisa do Estado de São Paulo) grant 2018/12896-2 (ASB), Programa Ciências sem fronteiras, CNPq, Brazil grant 205952/2014-3 (CH), and FAPESP grant 2020/02678-8 (FJP). The funders had no role in study design, data collection

Abstract

Leptospirosis, a zoonosis with worldwide distribution, is caused by pathogenic spirochetes belonging to the genus *Leptospira*. Bacterial outer membrane proteins (OMPs), particularly those with surface-exposed regions, play crucial roles in pathogen dissemination and virulence mechanisms. Here we characterized the leptospiral Membrane Protein L36 (MPL36), a rare lipoprotein A (RlpA) homolog with a C-terminal Sporulation related (SPOR) domain, as an important virulence factor in pathogenic *Leptospira*. Our results confirmed that MPL36 is surface exposed and expressed during infection. Using recombinant MPL36 (rMPL36) we also confirmed previous findings of its high plasminogen (PLG)-binding ability determined by lysine residues of the C-terminal region of the protein, with ability to convert bound-PLG to active plasmin. Using Koch's molecular postulates, we determined that a mutant of *mpl36* has a reduced PLG-binding ability, leading to a decreased capacity to adhere and translocate MDCK cell monolayers. Using recombinant protein and mutant strains, we determined that the MPL36-bound plasmin (PLA) can degrade fibrinogen. Finally, our *mpl36* mutant had a significant attenuated phenotype in the hamster model for acute leptospirosis. Our data indicates that MPL36 is the major PLG binding protein in pathogenic *Leptospira*, and crucial to the pathogen's ability to attach and interact with host tissues during infection. The MPL36 characterization contributes to the expanding field of bacterial pathogens that explore PLG for their virulence, advancing the goal to close the knowledge gap regarding leptospiral pathogenesis while offering a novel potential candidate to improve diagnostic and prevention of this important zoonotic neglected disease.

and analysis, decision to publish, or preparation of the manuscript.

Competing interests: The authors have declared that no competing interests exist.

Author summary

As part of their diverse virulence machinery, bacterial pathogens bind to human plasminogen (PLG) providing them with a proteolytic platform that promotes invasiveness, dissemination, and virulence. Leptospirosis is the leading zoonotic disease in morbidity and mortality worldwide. The burden of this neglected disease will continue to raise given the effects of climate change and social inequality, important drivers of disease. Furthermore, the gap of knowledge regarding leptospiral pathogenesis has negatively impacted the development of sensitive diagnostic tools and effective prevention methods. Previous studies have shown that pathogenic *Leptospira*, the causative agent of leptospirosis, can interact with PLG through different protein candidates. In this work, we characterized one of those candidates, Membrane Protein L36 (MPL36), as the main leptospiral plasminogen binding protein. Using genetically modified mutants, *in vivo*, and *in vitro* assays we provided evidence that MPL36 can bound PLG, promotes adherence to host cells and subsequent translocation, and degrades fibrinogen by converting bound-PLG to PLA, thus essential to leptospiral virulence. This work contributes to the growing field of bacterial pathogens exploring PLG to increase their virulence, while highlighting important new knowledge on leptospiral pathogenesis. MPL36 is an important candidate to be explored on the continued effort to improve diagnostic and prevention of this important zoonotic disease.

Introduction

Interaction with the human plasminogen (PLG) system significantly contributes to the virulence of many bacterial pathogens by equipping them with a proteolytic platform that enables bacterial invasiveness and tissue destruction [1]. Sequestration of PLG with further activation into plasmin (PLA) is crucial for bacterial survival in the host environment, since surface-bound PLA degrades fibrin clots, ECM molecules, and host's innate immune proteins facilitating dissemination and escape from immune responses [2,3]. The pathogenic spirochete *Leptospira*, the causal agent of the life-threatening infectious disease leptospirosis, is known to interact with host's fibrinolytic system to ensure dissemination during the infection process [4].

Leptospirosis is a zoonotic disease of worldwide occurrence, which has a significant public health impact especially in low-income tropical and sub-tropical countries [5]. Globally, more than one million cases and approximately 60,000 deaths from leptospirosis are estimated each year [6]. The severe form of leptospirosis, accounting for 10% of all cases, may be fatal due to bleeding manifestations and acute kidney injury. Mortality rates of up to 74% have been reported in patients who developed leptospirosis-associated pulmonary hemorrhage-syndrome [7–12]. The disease also affects the agricultural industry, causing abortions, infertility, and death in livestock [5,13]. Since there are no preventive measures to control the infection in humans, leptospirosis remains a threat in developing countries lacking proper sanitation systems [6,13,14].

Currently classified into 69 species, the genus *Leptospira* was recently grouped in two major clades, namely the “Saprophytes” composed of free-living, nonpathogenic species, and the “Pathogens” which comprise species known to cause disease in humans and animals (P1) or species whose virulence status awaits confirmation, formerly called “Intermediates” (P2) [15,16]. Pathogenic *Leptospira* enter the host through injured skin or mucous membranes, and rapidly reach the bloodstream [17,18], due to their efficient swimming and crawling motilities through viscous environments [19,20]. The first step in the process of leptospiral infection is

cellular adhesion, mediated by surface proteins interacting with various components of the extracellular matrix (ECM) [21]. Several putative adhesins that bind host ECM proteins have been identified in pathogenic *Leptospira* [22], but consistent evidence regarding cell/ECM-binding activity was only demonstrated for a few of them, such as the Leptospiral immunoglobulin-like proteins A (LigA) and B (LigB) [23] and the outer membrane protein L1 (OmpL1) [24]. These spirochetes are also equipped with additional mechanisms for host colonization, including the secretion of proteases that display proteolytic activity against ECM and plasma proteins [25], and the subversion of host proteases such as PLG through surface receptors [26,27]. Conversion of bound PLG into PLA by specific activators generates a proteolytic platform on the leptospiral surface supposedly increasing its invasiveness potential.

Several leptospiral proteins were previously described to act as PLG receptors. Some of them are well studied outer membrane proteins (OMPs) such as endostatin-like protein A (LenA), Leptospiral immunoglobulin-like proteins A (LigA) and B (LigB), and LipL32 [26,28,29]. Others are moonlighting proteins among which the elongation factor-thermal unstable (Ef-Tu) [30] and the metabolic enzyme enolase [31], also known to act as PLG receptors in other bacteria. The interaction of other less studied leptospiral surface proteins with PLG was also reported [28,32]. Of special interest within this group is the Membrane Protein L36 (MPL36) encoded in *Leptospira interrogans* strain Fiocruz L1-130 by the gene *lic10054*. MPL36 is a lipoprotein (321aa) with a Rare lipoprotein A (RlpA) domain (aa 22–257), initially described in *Escherichia coli* [33,34], a double-psi beta-barrel (DPBB) domain (aa 104–196), and a C-terminal Sporulation related (SPOR) domain (aa 248–318) [35] (Fig 1A). RlpA is localized at the septal ring in *E. coli*, but a precise role for this protein has not yet been defined in this organism, since no obvious phenotype associated with cell division was observed in *rlpA* mutants [33]. In *Pseudomonas aeruginosa*, RlpA was characterized as a peptidoglycan




Fig 1. Structure and surface localization of MPL36 in *L. interrogans* serovar Manilae L495 and rMPL36 interaction with host epithelial cells. (A) Predicted model of *L. interrogans* MPL36 with the double-psi beta-barrel domain (DPBB) (blue), a conserved region of RlpA proteins (green), and the SPOR domain (red) in the C-terminal. (B) Immunogold labeling of WT, $\Delta mpl36$, and $\Delta mpl36^+$ *Leptospira* strains were performed using polyclonal rabbit antiserum against MPL36 and goat anti-rabbit IgG labelled with 10 nm colloidal gold particles. Cells were visualized using 2% UA negative staining. (C) Whole intact spirochetes were incubated with different concentrations of Proteinase K (25–100 $\mu\text{g}/\text{mL}$), and western-blot analysis was conducted using polyclonal rabbit antisera against MPL36, LigA (positive control), and GroEL (negative control). (D) Recombinant proteins coated with fluorescent latex beads were incubated with immobilized MDCK cells and this interaction was assessed by fluorescent emission. LigA and LigB were used as positive control, while FlaA2 was used as negative control. The results are represented as mean \pm standard deviation of two independent experiments.

<https://doi.org/10.1371/journal.ppat.1011313.g001>

hydrolase digesting "naked" glycans, and the protein was shown to be crucial for proper separation of daughter cells and maintenance of rod morphology [36,37]. In pathogenic *Leptospira*, MPL36 was shown to bind human PLG with high affinity, presenting the lowest dissociation constant (K_D) value among all proteins tested [32]. In the current study, using a random mutant [38] that lacked expression of MPL36, we performed genomic manipulation, *in vivo* studies, and *in vitro* assays to demonstrate that the PLG-binding MPL36 protein is necessary for pathogenic *Leptospira* to disseminate within the host and successfully establish infection.

Results

Complementation restores expression of the MPL36 protein and disruption of *mpl36* does not affect cell motility and growth rate

L. interrogans serovar Manilae $\Delta mpl36$ mutant strain was generated by Himar1 transposon mutagenesis, with the transposon insertion on position 921,626 of the Manilae genome (558 bp from the start codon of the gene) (S1A Fig). The complemented strain was generated by the insertion of the transposon carrying the gene *mpl36* and a spectinomycin resistance cassette. After semi-PCR and sequencing screening, we identified four complemented strains, all of which exhibited the transposon in an intergenic region. The complemented strain Manilae $\Delta mpl36^+$, with the complementing construct inserted at chromosome position 292,919, was chosen for this study (S1A Fig). PCR and Sanger sequencing confirmed the presence of the *mpl36* gene in the WT and complemented strains.

Immunoblotting of bacterial whole-cell lysates with a rabbit polyclonal antibody raised against rMPL36 allowed detection of the native protein in both the WT and complemented ($\Delta mpl36^+$) strains. A specific protein band with the apparent molecular mass of ~40 kDa was not visible in the mutant ($\Delta mpl36$) strain (S1B Fig). This result confirmed the disruption of *mpl36* gene, and consequently, lack of expression of MPL36 in the mutant, as well as restoration of protein production by the complemented strain. It is important to note that a faint band is still visible on our mutant (S1B Fig) potentially as a result of a non-functional portion of the protein still being expressed (*lic10054* gene was disrupted and not completely removed) or unspecific binding to another protein of similar molecular mass. Furthermore, the phenotypes described below show evidence of complete disruption of the functional MPL36 protein in our mutant strain.

No differences in cell morphology were observed among the different strains. Based on these facts, we assessed cell motility and growth ability of our Manilae strains. Using motility plate assays, no differences in motility (S1C Fig) were observed while comparing the wild-type (32 ± 1 mm), with $\Delta mpl36$ mutant (31 ± 1 mm, $p = 0.2254$), and complemented (30.7 ± 0.7 mm, $p = 0.6667$) strains. Similarly, comparable growth rates in EMJH medium at 30°C were exhibited by all three strains (S1D Fig), indicating that the disruption of the *mpl36* gene does not affect motility and the ability of the strain to multiply and grow *in vitro*.

MPL36 is a surfaced exposed *Leptospira* protein that binds to host cells and PLG

MPL36 was predicted to be an outer membrane lipoprotein according to *in silico* analysis using lipoP and TMHMM software, and by immunofluorescence assay in a previous study [28]. Immunogold labeling using the WT, $\Delta mpl36$, and $\Delta mpl36^+$ strains demonstrated that anti-MPL36 antibodies specifically labeled the surface of the WT and $\Delta mpl36^+$ strains and did not bind to the surface of the $\Delta mpl36$ strain (Fig 1B). Surface exposure was further assessed by proteinase K treatment of intact leptospires (*L. interrogans* serovar Manilae L495). Both

MPL36 and the well-characterized surface protein LigA [5,23] were sensitive to proteinase K-mediated degradation while the cytoplasmic control protein GroEL was not, providing additional evidence for MPL36 cell surface localization (Fig 1C). Immunoblot assay on the phase-partitioned fractions of *Leptospira* detected the MPL36 and surface LigA protein in the hydrophobic detergent phase, while the cytoplasmic protein GroEL [39] was partitioned into the aqueous phase, and the periplasmic protein FlaB [26] was detected in the protoplasmic cylinder fraction (S2A Fig). Using multiple methods, we confirmed here the subcellular localization of MPL36 in *Leptospira* as an outer membrane protein.

The role of rMPL36 in adhesion to mammalian cells and ECM components was further investigated. Fluorescent latex beads coated with rMPL36 bound to MDCK cells whereas uncoated beads or those coated with rFlaA2 (negative control) did not display cell-binding activity (Fig 1D). As expected, rLigA and rLigB (positive controls) exhibited significant binding to MDCK cells (Fig 1D).

The interaction of rMPL36 with ECM proteins and PLG was also evaluated. No significant binding to fibronectin ($p > 0.9$, Fig 2A) or laminin ($p = 0.9$, Fig 2B) was detected with rMPL36, unlike what was observed with rLigA and rLigB proteins (positive controls). However, as previously described [28], rMPL36 displayed a significant binding capacity to human PLG compared to all other recombinant proteins used either as positive or negative controls ($p < 0.0001$, Fig 2C).

Furthermore, rMPL36 is recognized by sera from individuals with laboratory confirmed severe leptospirosis from Salvador, Brazil. Convalescent sera from those individuals have a high level of antibodies against MPL36 in both IgM (S2B Fig) and IgG (S2C Fig) when compared to sera from healthy individuals ($p = 0.0023$ and $p < 0.001$). No statically significant difference was observed in the acute sera (S2B and S2C Fig), although 48% of these sera had IgM antibodies levels higher than the identified threshold (S2B Fig, $p = 0.08$), confirming its expression during host infection, as previously observed [28], and further suggesting a potential role on the initial phases of the disease.

Taken together, those results suggest that rMPL36 can directly associate with MDCK cells, which is consistent with its surfaced-exposed localization and expression in the host during leptospirosis, in addition to its ability to bind to PLG, as previously described [28,40].




Fig 2. Binding of rMPL36 to ECM components and plasminogen (PLG). 96-well plates were coated with 1 μ g of fibronectin (A), laminin (B), and PLG (C). 0.2 nmol of the recombinant proteins MPL36, LigA, LigB or FlaA2 coated with fluorescent latex beads were added per well, and the binding was assessed by fluorescent emission. A control using uncoated fluorescent latex beads was used to measure background signal. Data represent the mean \pm standard deviation of results from three independent experiments (NS = non significant; *** $p < 0.0001$).

<https://doi.org/10.1371/journal.ppat.1011313.g002>

MPL36 binds PLG by its C-terminal lysine residues and MPL36-bound PLG is converted to PLA

To be proteolytically active, PLG needs to be converted to its active form, PLA, by urokinase or tissue PLG activators (uPA or tPA, respectively). Previous analysis of rMPL36-bound PLG have demonstrated the role of lysine residues on this interaction and the ability of PLG to be converted to PLA [28]. By exogenously supplying uPA to rMPL36-bound PLG, we confirmed that the newly generated PLA was able to significantly cleave the chromogenic substrate D-valyl-leucyl-lysine- ρ -nitroanilide dihydrochloride compared to BSA control ($p < 0.001$) (Fig 3A). Significant PLA activity was not detected with rLigA, rLigB, or rFlaA2 (Fig 3A). rMPL36-PLG interaction was dose-dependently inhibited by EACA, a lysine analog that binds to the PLG Kringle domains, confirming the involvement of lysine residues in the binding of rMPL36 to PLG (Fig 3B). Moreover, by ligand affinity blotting, we showed evidence suggesting that the last 70 amino acids of the protein, related to the conserved SPOR domain [35], is the region of rMPL36 required to bind PLG. The aa41-305 construct bound PLG as did the intact rMPL36 (aa41-321), while the aa41-235 construct lacked binding activity (Fig 3C).

The SPOR domain of MPL36 has seven lysine residues (S3A Fig). Despite differences in amino acid composition, tertiary structures of the SPOR domain from *L. interrogans* (P1), *L. fainei* (P2), and *L. biflexa* (S1) were similar (S3B Fig) and aligned with a root mean square deviation (RMSD) of 0.497. The major differences are more evident on the localization of lysine residues among different species (S3B Fig). Phylogenetic analysis revealed that the amino acid identity of MPL36 varied between 100% and 86% within pathogenic species (P1) of *Leptospira*, indicating a high degree of conservation. In contrast, the aa similarity dropped to 64% and 50% identity for pathogenic species of the P2 group and saprophyte species (S1 and S2), respectively, with MPL36 clearly being able to separate all species in different branches (S3C Fig). When we compared the amino acid composition, there were major differences between aa 248 and aa 321 among pathogenic and saprophytic species (S3D Fig), which corresponds to the region identified as to be potentially essential for PLG binding (Fig 3C). Given the limitations of those findings, performed using recombinant proteins and without being able to




Fig 3. Characterization of plasminogen (PLG) binding to rMPL36. (A) MPL36-bound PLG activation to plasmin (PLA) by urokinase-type PLG activator (uPA). 96-well plates were coated with 1 μ g of rMPL36, rLigA, rLigB, rFlaA2 or BSA, and incubated with PLG (1 μ g). After activation with uPA (4 ng) and the chromogenic substrate (S) (0.4 mM), the reaction was measured using a fluorometer. Data represent the mean absorbance value at 405 nm \pm the standard deviation of three independent experiments ($*p < 0.001$). (B) Assessment of lysine residues involvement in MPL36/PLG interactions. PLG (10 μ g/mL) was added to MPL36-coated wells (1 μ g) in the presence of epsilon-aminocaproic acid (0.1–10 mM). Bound-PLG was detected with a polyclonal anti-PLG (1:2,000), followed by peroxidase-conjugated secondary antibodies (1:10,000). Data show the mean absorbance value at 492 nm \pm the standard deviation of three independent experiments ($*p < 0.05$; $**p < 0.01$). (C) Mapping of MPL36 region interacting with PLG by ligand affinity blot. Purified full-length (aa41-321) and truncated (aa41-305 and aa41-235) MPL36 recombinant proteins were subjected to SDS-12% PAGE under reducing conditions, transferred to a nitrocellulose membrane, and incubated with 50 μ g of purified human PLG. Bound PLG was detected with anti-human PLG (1:500) followed by peroxidase-conjugated anti-rabbit IgG (1:10,000). BSA was included as a negative control.

<https://doi.org/10.1371/journal.ppat.1011313.g003>

directly identify the specific site domain related to PLG binding, experiments using site-directed mutagenesis would be necessary to further confirm the role of the SPOR domain as the MPL36 PLG-binding site in pathogenic leptospires.

MPL36-bound PLG mediates fibrinogen degradation

Given the results with the rMPL36, we assessed the acquisition of human PLG in pathogenic *Leptospira* strains. The importance of MPL36 in PLG recruitment to the bacterial surface was endorsed by the reduced ability of the mutant strain to bind PLG ($p = 0.0097$), and by full restoration of PLG acquisition capacity by the complemented strain ($p = 0.0027$) (Fig 4A). Of note, although not statistically different from that displayed by the negative control strain Patoc (Fig 4A), the reduced but not completely abolished binding ability of the $\Delta mpl36$ knock-out strain to PLG indicates the existence of other proteins with similar function, as previously described [28,32].

We then assessed if MPL36-bound PLG, once converted to its active form PLA, could cleave ECM substrates and immune mediators of physiological importance. Recombinant protein, as well as *Leptospira* strains, were first incubated with PLG. After successive washes, preparations were incubated with fibrinogen, vitronectin, laminin, fibronectin, and C3b in the




Fig 4. MPL36 role on the ability of *Leptospira* cells to bind to PLG and to degrade fibrinogen (Fbg). (A) PLG binding to Patoc, Manilae WT, mutant $\Delta mpl36$, and $\Delta mpl36^+$ strains was assayed using a whole-cell enzyme-linked immunosorbent assay. A total of 1 μ g PLG was immobilized and incubated with 10^8 bacterial cells. Bound leptospires were detected using serum from a hamster infected with an attenuated Manilae strain, and pre-immune serum was used as a control. Data represent the mean \pm standard deviation of results of three independent experiments after subtracting the pre-immune serum data. (B) Fibrinogen degradation by immobilized rMPL36-PLA. Microtiter plate wells coated with rMPL36, rLIC10301, or BSA (10 μ g/mL), were incubated with purified human PLG (20 μ g/mL). After washes, fibrinogen (500 ng) and uPA (1 U) were added and incubated for up to 18 h. A western blot using anti-human fibrinogen (1:5,000) was performed. (C) Fibrinogen degradation by PLA bound to *Leptospira* strains (Manilae WT, $\Delta mpl36$, $\Delta mpl36^+$). Leptospires (10^8 cells) were incubated with purified human PLG (10 μ g), and after washes uPA (3 U) and fibrinogen (10 μ g) were added and incubated for up to 18 h. Leptospiral supernatants were collected and analyzed by western blot using anti-human fibrinogen (1:5,000). Controls excluding uPA or PLG were included. One experiment representative of three is shown. (D) Densitometric quantification of fibrinogen cleavage by *Leptospira* strains. Band intensities corresponding to α -, β -, and γ - fibrinogen chains in T_{0h} were arbitrarily set as 100%. Quantification of fibrinogen cleavage products at T_{4h} and T_{18h} (relative to T_{0h}) are shown. Data were analyzed with one-way ANOVA and Student t test ($*p < 0.05$; $**p < 0.001$). # = proteolytic products. Fibrinogen chains' position is represented in red (B and C) - α (73kDa), β (60 kDa), and γ (53 kDa).

<https://doi.org/10.1371/journal.ppat.1011313.g004>

presence of the PLG activator uPA for 4 h or 18 h. rMPL36-bound PLA cleaved fibrinogen α -chain in a time-dependently manner, producing a degradation fragment of ~50 kDa that co-migrates with fibrinogen γ -chain (Fig 4B). No degradation products were detected when the plates were immobilized with the negative control proteins BSA or rLIC10301, a lipoprotein of unknown function that is unable to bind PLG [30] (Fig 4B). As expected, fibrinogen degradation was much more pronounced when we used intact bacteria, with all three strains degrading both α and β chains of fibrinogen (Fig 4C). However, a more pronounced degradation was only achieved in the presence of the WT and the complemented strains after 18 h incubation period, thus indicating that MPL36, by acquiring PLG, effectively contributes to fibrinogen degradation (Fig 4C). Furthermore, in the presence of the $\Delta mpl36$ strain the degradation products detected in the absence of active PLA (uPA + Fbg and PLG + Fbg) were similar to those observed in the presence of PLG (PLG + uPA + Fbg), thus indicating that this degradation results from non-PLA action, most likely leptospiral proteases.

Fibrinogen degradation in the presence of both the WT and complemented strains at 18 h was significantly more efficient ($p = 0.0447$ and $p = 0.0119$, respectively) compared to the one observed in the presence of the mutant strain (Fig 4D). As ECM and complement proteins are among PLA targets, we also assessed the ability of MPL36-bound PLA to degrade vitronectin (S4A Fig), laminin (S4B Fig), and complement C3b (S4C Fig). No differences regarding the degradation patterns were observed for the WT, $\Delta mpl36$ and $\Delta mpl36+$ strains (S4A–S4C Fig), thus indicating that MPL36-bound PLA specifically targets fibrinogen. Complete degradation of vitronectin probably results from the action of bacterial secreted proteases since the cleavage profiles are quite similar for all three strains (S4A Fig). Taken together, those results indicate that MPL36 is a major PLG binding protein with a potential contribution to the proteolytic ability of pathogenic leptospires, which could increase the invasiveness capacity of this bacterium.

Native MPL36 promotes *Leptospira* adhesion to epithelial host cells and translocation

To further confirm the adhesive and invasiveness properties of MPL36 on epithelial cells, the interaction of Manilae WT, $\Delta mpl36$, and $\Delta mpl36^+$ strains with cultured MDCK cells was investigated. The saprophyte Patoc strain was included as a negative control. An average of 6 WT leptospires adhered to each MDCK cell while approximately 0.2 and 0.5 of mutant and saprophytic leptospires, respectively, were found associated with each MDCK cell (Fig 5A). The binding capacity of the mutant strain was significantly reduced compared to the ones displayed by the WT ($p = 0.001$) and the complemented strain ($p = 0.0107$), but the phenotype of adherence was not completely restored on the complemented strain (average of 4 leptospires/MDCK cell) when compared to the WT ($p = 0.0452$, Fig 5A).

We also investigated the ability of these *Leptospira* strains to translocate through monolayers of MDCK cells. Within the first two hours after infection, only the WT and complemented strains were recovered from the lower chamber of the Millicell culture plates, indicating their ability to successfully cross the MDCK cell monolayers (Fig 5B). The mutant strain ($\Delta mpl36$) was recovered starting at 4 h post-infection. However, over the 8-hour course of the experiment, there is a statistical difference in the number of mutant cells that were recovered compared to the WT ($p = 0.0284$) and complemented strains ($p = 0.0456$). There were no statistical differences between the numbers of WT and complemented strains recovered ($p = 0.0625$), indicating that the complementation restored the ability of the mutant to translocate. As expected, the Patoc strain was unable to successfully translocate, as previously observed [41] (Fig 5B). Consistent TEER measurements indicated that disruption of cell monolayers' TJ did




Fig 5. Role of MPL36 on the pathogenesis of *Leptospira interrogans*. (A) Ability of leptospire strains to adhere to MDCK epithelial cells. Manilae WT, $\Delta mpl36$, and $\Delta mpl36^+$ strains were incubated with immobilized MDCK cells for one hour at 37°C and adhesion assessed by immunofluorescence. Data represent the mean \pm standard deviation of results from three independent experiments. (B) Ability of *Leptospira* strains to translocate through polarized monolayers of MDCK cells. The Patoc strain was used as negative control. Strains were inoculated (100 MOI) in the upper chamber of a Millicell culture plate containing MDCK cell monolayer. Percent recovery of leptospires was determined by counting bacteria in the lower chamber between 0 and 8 hours after inoculation. Right Y axis shows TEER measurements. Data represents the mean \pm standard deviation of results from three independent experiments. (C, D) Survival curve of hamsters infected with *Leptospira* strains. Animals were infected either by intraperitoneal (IP) or conjunctival (CJ) route with 10^8 leptospire. Data represent results of one of two independent experiments.

<https://doi.org/10.1371/journal.ppat.1011313.g005>

not occur during the translocation process (Fig 5B). Taken together, those experiments indicate that MPL36 abrogation partially impairs the ability of leptospire to adhere to and translocate through polarized monolayers of MDCK cells, which in turn would affect the ability of the pathogen to efficiently disseminate and cause disease.

MPL36 is essential for virulence of pathogenic *Leptospira* during acute infection

To determine the role of MPL36 during the infection process, the WT, $\Delta mpl36$ and $\Delta mpl36^+$ strains were tested for virulence in the hamster model of leptospirosis infection. Hamsters challenged by IP route with 10^8 leptospire of the $\Delta mpl36$ strain survived up to 21 days without any symptoms of infection, whereas hamsters challenged with the same number of bacteria of the WT strain died between 3–5 days post-infection (Fig 5C and S2 Table). The mutant phenotype complemented by reintroduction of *mpl36* yielded 100% lethality at dose 10^8 in 4–6 days after IP challenge (Fig 5C and S2 Table).




Fig 6. Schematic summary view of MPL36 role on leptospiral pathogenesis. Hypothetical model showing how acquisition of PLG by MPL36 contributes to *Leptospira* adhesion and translocation through cell monolayers, and to the proteolytic potential of this spirochete.

<https://doi.org/10.1371/journal.ppat.1011313.g006>

When using the CJ route of infection, hamsters challenged with 10^8 leptospires with the $\Delta mpl36$ mutant survived without disease manifestation, whereas all animals challenged with the WT strain died between days 8–9 post-infection (Fig 5D and S2 Table). Animals infected with the complemented strain all died between 9- and 11-days post-infection (Fig 5D and S2 Table). Leptospires were not detected in the kidney of animals infected with $\Delta mpl36$ by both routes of infection at day 21 post-infection, when animals were euthanized (S2 Table). Those results indicate that MPL36 is an essential protein for the pathogenesis of *Leptospira* (Fig 6).

Discussion

Our results showed that MPL36 is an outer membrane protein acting as a major PLG binding in pathogenic *Leptospira*, with the ability to degrade fibrinogen, being essential for leptospiral virulence. The mechanisms behind the pathogenesis of leptospiral infection continues to be a major knowledge gap preventing the advance on diagnostic and prevention. Despite the recent major breakthroughs on the research of this important neglected zoonotic disease [21], more work is needed to better understand how leptospires can rapidly disseminate, evade host-immune responses, and cause life-threatening disease worldwide. A previous study has shown that only virulent strains of *Leptospira* spp. were capable of acquiring PLG from human plasma, strongly suggesting the involvement of this process in leptospiral virulence [27]. Through capturing PLG on their surface, followed by activation to PLA, these spirochetes augment their proteolytic capacity, and consequently, potentiate dissemination through tissue barriers. It has also been suggested that direct binding of fibrinogen to the leptospiral surface could lead to an increased consumption of those molecules, causing a reduction in fibrin clot formation [42]. *Leptospira* proteome contains multiple proteins with the ability to bind different ECM and PLG [4,32]. However, those studies were conducted using recombinant proteins and none of those targets have been confirmed to have a direct role in virulence.

The leptospiral MPL36 belongs to a family of proteins containing a Rare lipoprotein A (RlpA) domain [43] and a C-terminal SPOR (sporulation related repeat) domain [35]. Similar to its homologous in *E. coli* and *P. aeruginosa* [37,44], MPL36 has been characterized as a putative surface exposed protein in *Leptospira* [28,40]. The gene *mpl36* has been shown to be up-regulated in a dialysis membrane chamber (DMC) system implanted in the peritoneal cavities of

rats [45], representing a mammalian host-adapted state, and it has been identified as one of the genes regulated by *Leptospira* virulence regulator (*lvrAB*) [46], a signaling system that controls virulence in *Leptospira*. More recently, MPL36 has been identified as one of the targets associated as correlates of cross-protection on an attenuated-vaccine model for leptospirosis [47]. Furthermore, we demonstrated that human patients with leptospirosis produced antibodies that recognize MPL36 [40], and that IgM antibodies against MPL36 are detected during the early stages of the disease, thus indicating that MPL36 is expressed during host infection, has an important role on pathogenesis, and might serve as a target for serodiagnosis and vaccine development.

MPL36 was first characterized as a PLG-binding molecule in a study aiming to identify *Leptospira* PLG receptors [28]. In this study, we explored further the interaction of MPL36 with PLG by evaluating the functional consequences of PLG acquisition by leptospires through this surface receptor as well as leptospiral virulence in the absence of *mpl36*. Our results with both recombinant protein and mutant *Leptospira* strains not only confirmed the ability of MPL36 to bind to host epithelial cells, but also demonstrated that a mutant unable to express MPL36 (Δ *mpl36*) had an impaired binding capacity to PLG, similar to the phenotype observed for the saprophyte *L. biflexa*. The process of PLG binding to bacterial receptors on the cell surface has been shown for several pathogens to be mediated by the PLG Kringle domains containing lysine-binding sites [1]. Our results based on ligand affinity blotting and *in silico* analysis suggested that the PLG-interacting region of MPL36 is located at the SPOR domain on the protein C-terminus, with binding potentially occurring through lysine residues within this domain, respectively. However, further in depth experiments are needed to confirm those findings and potentially identify the particular site domain for this interaction.

SPOR domains are about 70 amino acids long consisting of four antiparallel β -sheet flanked on one side by two α -helices. The domain primary structure is not highly conserved, but it is present in several bacteria as a peptidoglycan (PG) binding domain and its function is mainly related to remodeling the PG sacculus during cell division [35,36]. Most bacterial SPOR domain proteins are present in the periplasm, although both *P. aeruginosa* and *E. coli* RlpA are outer membrane proteins [34,37]. *P. aeruginosa* outer membrane RlpA was described as a lytic transglycosylase [37], with mutants having striking morphological defects. However, none of the *E. coli* SPOR proteins have been reported to have an enzymatic activity [48] or being related to growth or cell viability [34]. MPL36 binding to PG and participation in cell division were not directly assessed in this study. However, the Δ *mpl36* strain had no morphological or growth defects, strongly suggesting that MPL36 is not involved in these processes in *Leptospira*. Although found in all *Leptospira* species, with 50% amino acid identity in the saprophyte *L. biflexa*, our *in-silico* analysis disclosed differences in primary structure composition, mainly clustered on the SPOR domain of the protein, suggesting a potential different function of this protein in non-pathogenic species.

MPL36-mediated PLA formation has a role on fibrinogen degradation in pathogenic leptospires. When incubated with rMPL36, we observed only a partial yet significant degradation of fibrinogen α -chain. This result suggests the existence of additional PLG-interacting proteins on the leptospiral surface able to degrade fibrinogen, as previously reported [4,26,32,49]. This assumption is further supported by the fact that *Leptospira* binding to PLG, although significantly reduced, was not completely abolished when we used the Δ *mpl36* mutant strain. It is also important to highlight that fibrinogen degradation by *Leptospira* results from two distinct mechanisms: PLA-binding activity and proteolytic action of extracellular metalloproteases secreted by virulent strains, which target ECM and plasma proteins from the host [25]. The combined strategies ensure an efficient degradation of host fibrinogen by *Leptospira* as demonstrated here. However, after 18 h of incubation almost complete hydrolysis of this

coagulation cascade molecule was observed only when WT or $\Delta mpl36^+$ strains were incubated with PLG, uPA and fibrinogen. Curiously, our experiments showed that MPL36-bound PLA had no apparent effect on vitronectin, laminin or complement C3b. Taken together, our results indicate that the MPL36-bound PLA seems to have an essential and targeted role on fibrinogen degradation, and more studies are needed to confirm and better understand this peculiar activity.

MPL36 mediates binding of leptospires to MDCK cells, a crucial step for subsequent translocation through cell monolayers. Studies have shown that in *Streptococcus* sp. the adherence process for colonization and translocation were dependent of PLG recruitment in the surface, with PLG acting as a linker molecule independently of the plasmin activity [50,51]. rMPL36 did not bind purified fibronectin or laminin, indicating the possibility that MPL36-bound PLG could anchor leptospires to the cell surface, serving as a bridging molecule. There is no evidence of ECM degradation related to MPL36, thus the inability of $\Delta mpl36$ strain to translocate could be strongly related to the low capability to adhere to host cells. Nevertheless, lack of expression of MPL36 in pathogenic *Leptospira* lead to a complete attenuation phenotype in hamsters, challenged by both IP and CJ routes, with the latter mimicking a more natural route of infection that involves adhesion and translocation of host cells. Bacterial PLG receptors are described as multifunctional surface proteins during infection process [1], and it has been shown that lysine residues must be precisely positioned during presentation to substrates and catalysts in order to activate the plasminogen system [52], thus influencing the pathogenic process. For that reason, further experiments are needed to understand the mechanism of action for MPL36 during the infectious process and other potential roles that MPL36 might have on the leptospiral pathogenesis process, leading to the observed attenuated phenotype.

In this study, we characterized the MPL36 protein as a surface exposed virulence factor, with the ability to bind to PLG and degrade fibrinogen, playing a role on adhesion and subsequent translocation of the leptospiral spirochete on host cells (Fig 6). Genetic manipulation tools for targeted mutagenesis in *Leptospira* are still limited and restricted to a few research laboratories, and the identification and characterization of leptospiral proteins' interaction with host components have been mostly based on recombinant proteins. Our results are based on *in vitro* and *in vivo* analysis using knockout and complemented mutants, fulfilling molecular Koch's postulates, providing new insights regarding bacterial proteins that explore PLG for their pathogenesis. There is a major interest in the identification of antigenically conserved surface-exposed proteins with the capacity to serve as broader vaccine candidate targets. In addition, the characterization of leptospiral components contributing to pathogenesis would aid in the development of improved diagnostic strategies. Our results demonstrate that MPL36 is a highly conserved protein among pathogenic species, expressed and able to elicit immune response during the infection process, satisfying all the requirements to be further explored on research designed to better understand leptospiral pathogenesis and advance diagnostic and prevention of this important zoonotic disease.

Material and methods

Ethics statement

The protocol of animal experimentation was prepared and approved according to the guidelines of the Institutional Committee for the Use of Experimental Animals, Yale University (protocol # 2023–11424).

Bacterial strains, cells, and culture conditions

The pathogen *Leptospira interrogans* serovar Manilae strain L495 (Manilae WT), the Manilae *mpl36* mutant ($\Delta mpl36$), the Manilae *mpl36* mutant complemented strain ($\Delta mpl36^+$) and the

saprophyte *L. biflexa* serovar Patoc strain Patoc 1 (Patoc) were grown in Ellinghausen-McCullough-Johnson-Harris (EMJH) liquid medium [53] with agitation or on 1% agar plates at 30°C. *E. coli* cells were grown in Luria-Bertani (LB) medium at 37°C with agitation. When appropriate, spectinomycin and/or kanamycin were added to the culture medium at a final concentration of 50 µg/mL. Madin–Darby canine kidney (MDCK) cells were cultured in minimum essential medium (MEM) containing 10% fetal bovine serum (GIBCO Laboratories). Cells were grown at 37°C in a humidified atmosphere with 5% CO₂.

For growth curves of WT, mutant and complemented strains, bacteria were initially enumerated under dark-field microscopy by using Petroff-Hausser counting chambers (Fisher Scientific) and diluted to a starting bacterial concentration of 10⁴ mL at 30°C. Growth was monitored daily by counting. Three independent experiments were performed. For the motility assay, 5 µL of 10⁵ leptospores were inoculated on 0.5% agarose EMJH plates and incubated for 10 days at 30°C, as previously described [41]

Proteinase K treatment of intact bacteria

MPL36 cell surface localization was first assessed by proteinase K treatment as previously described [39]. Briefly, Manilae WT cells were grown to a density of 5×10⁸ cells/mL and harvested by low-speed centrifugation at 2,000 × *g* for 10 min at room temperature. The pellet was gently washed with phosphate buffered saline (PBS) containing 5 mM MgCl₂, and collected by centrifugation at 2,000 × *g* for 10 min. After resuspension in PBS-5 mM MgCl₂, proteinase K (Sigma-Aldrich) diluted in proteolysis buffer (10 mM Tris-HCl pH8.0, 5 mM CaCl₂) was added to the washed leptospores in a final concentration of 25 to 100 µg/mL. Proteolysis buffer without proteinase K was added to the negative control. The reaction was quenched by the addition of phenylmethylsulfonyl fluoride (PMSF). Leptospores were subsequently collected by centrifugation and washed twice with PBS-5 mM MgCl₂, and the cells were resuspended in sample buffer for SDS-PAGE. Immunoblot analysis was performed using rabbit antibodies against proteins MPL36, LigA and GroEL at a dilution of 1:1,000. Bound antibodies were detected using horseradish peroxidase (HRP)-conjugated anti-rabbit IgG (GE Lifesciences) at a dilution of 1:100,000. Positive signals were detected by SuperSignal West Pico Kit (Pierce), according to the manufacturer's instructions, and blots were analyzed using ChemiDoc Imager (Bio-Rad).

Immunogold labeling

Bacterial cultures (1 × 10⁸ cells/mL) were centrifuged (6,500 × *g* for 20 min), washed with PBS three times and fixed with 4% formaldehyde for 30 min. After fixation, preparations were washed three times with PBS and blocked with 0.2% bovine serum albumin (BSA) in PBS (PBS-BSA) for 30 min. Preparations were then incubated overnight with rabbit anti-MPL36 antiserum (1:10 dilution in PBS) at 4°C. Subsequently, preparations were washed with PBS-BSA, and incubated with goat anti-rabbit antibody labeled with 10 nm colloidal gold particles (Sigma-Aldrich) diluted 1:10 in PBS, for 4h at room temperature. After further washings, preparations were mixed (1:1) with 2% uranyl acetate (UA) in water and placed onto Formvar-coated nickel grids for 2 min. After completely dried with filter paper, preparations were then analyzed under TEM (LEO 906E –Zeiss, Germany) at 80 kV.

Phase partitioning of *Leptospira* membrane proteins using Triton X-114

Phase separation of the integral membrane proteins of *Leptospira* to localize the protein MPL36 was performed using Triton X-114 solution as described elsewhere [54]. Briefly, a 50 mL mid-log-phase culture of *L. interrogans* serovar Copenhageni Fiocruz L1-130 (5×10⁹ cells)

was washed in PBS containing 5 mM MgCl₂. The membrane proteins were extracted at 4°C with 1% Triton X-114, 150 mM NaCl, 10 mM Tris (pH 8.0) and 1 mM EDTA. The insoluble debris was removed by centrifugation at 12,000 × g for 15 min and then 20 mM CaCl₂ was added to the supernatant. Phase separation was performed by warming the supernatant at 37°C and subjecting it to centrifugation for 10 min at 1,000 × g. The detergent and aqueous phases were separated and precipitated with 10 volumes of chilled acetone. The aqueous and detergent phases were then resolved onto 12% SDS-polyacrylamide gel before transferring to nitrocellulose membrane for immunoblot analysis using polyclonal rabbit sera anti-MPL36, anti-LigA, and anti-GroEL (1:1,000).

Cloning, expression, and purification of MPL36 fragments

The full recombinant MPL36 protein (rMPL36/aa 41–321) was commercially produced by GenScript Biotech with His-tag in an *E. coli* expression system. Recombinant MPL36 protein devoid of the last 16 residues (rMPL36/aa 41–305) and devoid of the last 86 residues (MPL36/aa 41–235) were produced following protocol previously described [39]. DNA fragments were amplified by PCR from *L. interrogans* serovar Copenhageni genomic DNA (strain Fiocruz L1-130) with set of primers aa41-305 and aa41-235, using restrictions enzyme sites for BamHI and NcoI, respectively (S1 Table). The amplified products were cloned into the pGEM-T Easy vector (Promega) and subcloned into the pAE expression vector [55]. This vector allows the expression of recombinant proteins with a minimal His6 tag at the N-terminus. The constructs were transformed into *E. coli* BL21 DE3. Expression and purification of the recombinant proteins were performed essentially as previously described [39]. Control protein rLIC10301 used in our experiments was expressed following the same protocol. The full rMPL36 and rLIC10301 proteins were purified from the supernatant of *E. coli* lysates, while the rMPL36 aa41-305 and rMPL36 aa41-235 were purified from the insoluble pellet, by nickel affinity chromatography. Tertiary structure of rMPL36, rMPL36 aa41-305, rMPL36 aa41-235 was assessed by intrinsic tryptophan fluorescence spectroscopy [56]. Data were collected using 1 cm path length rectangular quartz cuvettes on a fluorescence spectrophotometer (Cary Eclipse, Varian). Recombinant proteins (4 μM) were incubated in the presence or absence guanidine hydrochloride (GdnHCl, 6 M) for 30 min, and intrinsic fluorescence emission of folded and unfolded proteins was measured in 10 mM PBS, with excitation at 280 nm and emission recorded in the range of 300–400 nm. Full-length rMPL36 and the other 2 constructs display one aromatic and fluorescent tryptophan (Trp) residue. Intrinsic fluorescence spectrum of MPL36 showed a maxima emission wavelength (λ_{max}) at 335 nm, indicating that Trp is located at an apolar environment. The addition of 6 M GdnHCl resulted in a shift to 356 nm, a result compatible with the exposure of the aromatic side chains to the solvent and the total unfolding of the protein (S5 Fig). The same behavior was observed for the 2 other constructs, indicating that the three proteins were structured, but lost tertiary structure upon addition of GdnHCl (S5 Fig).

Binding assay using fluorescent latex beads

To assess the binding ability of rMPL36 to ECM proteins and PLG, 1 μg of fibronectin (10 nM, Sigma-Aldrich), laminin (20 nM, Sigma-Aldrich), PLG (100 nM, Sigma-Aldrich) and BSA (negative control) was coated on 96-well plates overnight at 4°C. Plates were blocked for 1 h at 37°C with 5% non-fat dried milk in 2% BSA. Recombinant proteins MPL36, FlaA2 (negative control), non-identical regions of LigA (rLigA; amino acid positions 625 to 1225) and LigB (rLigB; amino acid positions 625 to 1257) (positive controls) were diluted in PBS to a final concentration of 0.2 nmol. A 4 μL sample of the stock suspension of latex beads (containing about

3×10^{10} mL⁻¹ of 0.3 μ m diameter beads, Sigma-Aldrich) was added to each protein and incubated for 2 h at 37°C. A sample of 100 μ L of this suspension was then added in triplicate to the wells of the previously coated plates and incubated for 2 h at 37°C. Plates were washed four times with PBS-0.05% (vol/vol) Tween 20 (PBST) and the fluorescent emission (excitation at 486–580 nm and emission at 568–590 nm) was measured using Synergy HT (BioTek, Agilent). Uncoated beads and beads coated with BSA were used as controls. For statistical analyses, the experiment was repeated three times and the attachment of recombinant proteins to the host components was compared to its binding to BSA.

To assess the binding ability of rMPL36 to host epithelial cells, Madin-Darby Canine Kidney (MDCK) cells were seeded in a 24-well tissue culture plate at a density of 2×10^5 cells per well and incubated at 37°C with 5% CO₂ for 48 h until the formation of a near-confluent MDCK cell monolayer. Samples of 100 μ L of the latex bead suspension coated with rMPL36, rFlaA2, rLigA and rLigB, as described above, were added in triplicate to the pre-incubated MDCK cells. After 5 h incubation at 37°C, cells were washed three times with PBS. The fluorescence emission was measured directly in the 24-well plate using Synergy HT (BioTek, Agilent). The experiment was repeated twice.

Conversion of PLG into active PLA

To evaluate if PLG bound to rMPL36 is converted into active PLA 96-well plates were coated with 0.2 μ M of recombinant proteins or BSA (negative control) at 4°C overnight. The plates were washed once with PBST and blocked 2 h at 37°C with 10% non-fat dried milk in PBS. The blocking solution was discarded, and the plate washed four times with PBST. Then, 1 μ g (100 nM) of human PLG (Sigma-Aldrich) was added to each well and incubated for 2 h at 37°C. Wells were washed four times with PBST, and then 4 ng (0.7 nM) of human urokinase-type PLG activator (uPA, Sigma-Aldrich) was added per well. After that, 100 μ L of the PLA specific substrate D-valyl-leucyl-lysine-p-nitroanilide dihydrochloride (Sigma-Aldrich) was added at a final concentration of 0.4 mM in PBS. Plates were incubated overnight, and substrate degradation was measured at 405 nm using Synergy HT (BioTek, Agilent). The experiment was repeated three times for reproducibility.

Role of lysins in rMPL36-PLG interaction

To assess the role of lysins in rMPL36-PLG interactions 96-well plates were coated with rMPL36 (10 μ g/mL, 200 nM). After blocking with 3% BSA, PLG (10 μ g/mL, 100 nM) and ϵ -aminocaproic acid (0–10 mM) were added to the coated wells. Bound PLG was detected with a rabbit polyclonal antibody (Sigma-Aldrich) at a 1:2,000 dilution followed by peroxidase-conjugated anti-rabbit IgG (Sigma-Aldrich) at a 1:10,000 dilution. Student's two-tailed *t* test was used for statistical analyses.

Interaction of rMPL36 with PLG by ligand affinity blotting

Purified recombinant proteins were subjected to 12% SDS-PAGE and transferred to a nitrocellulose membrane. After blocking with 5% BSA the membrane was incubated for 1 h with 50 μ g (200 nM) of purified PLG (Sigma-Aldrich) diluted in PBS. After five washes with PBST, the membrane was incubated with polyclonal rabbit antibodies recognizing human PLG (Sigma-Aldrich, 1:500), followed by peroxidase-conjugated secondary antibodies (1:10,000). Positive signals were detected by SuperSignal West Pico Kit (Pierce). BSA was used as a negative control.

Detection of antibodies to rMPL36 using human sera of individuals with laboratory-confirmed leptospirosis

We performed an ELISA assay using rMPL36 against acute and convalescent sera from 29 individuals with confirmed severe leptospirosis enrolled in our surveillance study in Salvador, Brazil [14]. Control human sera were obtained from healthy US human donors. Microtiter plates (Corning) were coated with 80 ng of rMPL36 and incubated overnight at 4°C. The plates were washed three times with PBST and incubated with 5% milk blocking solution for 2 h at 37°C. After four washes with PBST, wells were incubated in duplicate with human immune sera, diluted 100-fold in 2% BSA, for 1 h at 37°C. Secondary anti-IgM human HRP conjugated antibody (Sigma-Aldrich) or anti-IgG human HRP (Jackson ImmunoResearch) was used at a dilution of 25,000 (2% BSA) and incubated for 1 h at 37°C. Tetramethylbenzidine (TMB, SureBlue Reserve) was used for detection and the reaction was stopped by adding 100 μ L of 2 N H₂SO₄. Absorbance (450 nm) was recorded using Synergy HT (BioTek, Agilent). A threshold was calculated based on 2.5 SD of the average OD from the healthy individuals for each isotype.

Insertion mutagenesis and complementation

Random mutagenesis in *L. interrogans* serovar Manilae strain L495 using mariner-based transposon *Himar1* has been previously described [38]. The insertion site was identified by semi-random PCR followed by DNA sequencing. The insertion within *mpl36* was confirmed by PCR using primers flanking the insertion site. For complementation, *mpl36* and its native promoter were PCR amplified from Manilae WT using primers *mpl36F* and *mpl36R*, designed with KpnI restriction sites (S1 Table). The amplicon was then digested by KpnI and ligated into plasmid pAL614, which carries a modified *Himar1* transposon for conjugation [57] containing a spectinomycin resistance cassette. The resulting plasmid (pAL614-*mpl36*) was used to chemically transform *E. coli* S17 cells, which were subsequently used to transform serovar Manilae Δ *mpl36* strain via conjugation. Transposon insertion occurred at nucleotide 292,919 in the gap of two open reading frames. MPL36 expression by the mutant (Manilae Δ *mpl36*) and complemented (Manilae Δ *mpl36*⁺) strains was verified by Western-blot analysis using anti-MPL36, as described above.

Binding of *Leptospira* strains to PLG

Adhesion of *Leptospira* strains (Manilae WT, Δ *mpl36*, Δ *mpl36*⁺, and Patoc) to human PLG (Sigma-Aldrich) was assessed by ELISA as previously described [23]. A 96-well plate was coated with PLG or BSA (negative control) (10 μ g/mL) overnight at 4°C. Plates were washed four times and then blocked with 5% non-fat dried milk in 2% BSA for 1 h at 37°C. After washing with PBST, 1 \times 10⁸ leptospires were added to each well and incubated for 90 min at 37°C. After two washes with PBST to eliminate non-adherent cells, adherent leptospires were fixed with cold-methanol for 10 min at -20°C, and detected with a hamster polyclonal serum of animals infected with 10⁷ *L. interrogans* serovar Manilae *fcpA*⁻ [41] (1:1,000) followed by a peroxidase-conjugated anti-hamster IgG (1:50,000). Pre-immune serum was used as a negative control, and final values were calculated from three technical results after subtracting the pre-immune serum data. Absorbance was measured at 405 nm using Synergy HT (BioTek, Agilent).

ECM and plasma protein degradation by PLA bound to *Leptospira* strains

Mid-log phase leptospires (Manilae WT, Δ *mpl36*, Δ *mpl36*⁺) were harvested by centrifugation at 9,000 \times g for 5 min and 1 \times 10⁸ bacteria were incubated with purified human PLG (10 μ g,

1 μM) diluted in PBS for 1 h at 37°C. Leptospire were washed three times with PBS and then incubated with 3 U of uPA (Sigma-Aldrich) and 10 μg (300 nM) of human PLG-depleted fibrinogen (Calbiochem), or 2.5 μg (300 nM) of human vitronectin (Sigma-Aldrich), or 5 μg (50 nM) of laminin (derived from mouse Engelbreth-Holm-Swarm sarcoma, Sigma-Aldrich), or 2.5 μg (50 nM) of human plasma fibronectin (Sigma-Aldrich), or 1.5 μg (80 nM) of human complement C3b (Complement Technology) at 37°C for 0, 4 and 18 h. For the control reactions, either PLG or uPA was omitted. After incubation, leptospiral supernatants were collected by centrifugation and subjected to 12% SDS-PAGE. The cleavage fragments were analyzed by western blot with either mouse anti-human fibrinogen polyclonal antibody (Sigma-Aldrich) at a 1:5,000 dilution, rabbit anti-human vitronectin polyclonal antibodies (Complement Technology) at a 1:5,000 dilution, rabbit anti-human laminin polyclonal antibodies (Sigma-Aldrich) at a 1:5,000 dilution, rabbit anti-human fibronectin polyclonal antibodies (Sigma-Aldrich) at a 1:5,000 dilution, or goat anti-human C3 polyclonal antibodies (Complement Technology) at a 1:5,000 dilution, followed by peroxidase-conjugated anti-mouse (1:5,000), rabbit or goat (1:10,000) IgG (Sigma-Aldrich). Positive signals were detected by SuperSignal West Pico Kit (Pierce). Images of the three experiments performed were recorded and band intensities were quantified using the Alliance LD2 system (Uvitec, Cambridge, UK). Band intensities at 0 h, corresponding to α -, β -, and γ -fibrinogen chains, were arbitrarily set as 100%.

Degradation of fibrinogen by rMPL36 was also assessed. rMPL36, and negative controls rLIC10301 [30] and BSA (10 $\mu\text{g}/\text{mL}$, 200 nM) were immobilized on microtiter plate wells and blocked with 3% BSA diluted in PBS. PLG (20 $\mu\text{g}/\text{mL}$, 200 nM) was added, and plates were incubated for 1 h at 37°C. Wells were then washed six times with PBST and added with human fibrinogen (500 ng/well, 30 nM, PLG depleted; Calbiochem) and uPA (1 U/well). Reaction mixtures were incubated at 37°C for the indicated time points and were then separated by 12% SDS-PAGE. The degradation products of fibrinogen were detected by Western blot using rabbit anti-human fibrinogen polyclonal antibodies (Sigma-Aldrich) at a 1:5,000 dilution as described above.

Adherence to and translocation of leptospire through MDCK cells

Adherence of leptospire to MDCK cells was assessed as previously described [23]. MDCK cells (1×10^5) were added to round coverslips in 24-well plates and incubated until the formation of a near-confluent MDCK cell monolayer. *Leptospira* cells were incubated with MDCK at a multiplicity of infection (MOI) of 100 for 1 h at 37°C in 5% CO_2 . Following incubation, the suspensions were removed, and the monolayers were washed six times with warm PBS. The cells were fixed with pre-cold (-20°C) methanol for 10 min at 4°C, followed by three washes. Blocking buffer (10% fetal bovine sera in PBS) was then added to each well and incubation proceeded for 1 h at 37°C. To detect the adherent cells, a rabbit polyclonal antiserum against the protein LipL32 of *Leptospira* was used as primary antibody at a concentration of 1:200, followed by goat anti-rabbit antibodies conjugated with Alexa488 (Jackson ImmunoResearch) both at a concentration of 1:200 diluted in blocking buffer. Incubations were performed at 37°C for 1 h followed by three washes with PBS. After the final wash, the coverslips were removed from the 24-well plates, stained with DAPI, and mounted on a glass slide. Fluorescent-labeled leptospire associated to 100 MDCK cells on each of three poly-D-Lysine treated glass coverslips were enumerated. These three coverslips served as technical replicates for each strain tested during each trial.

Bacterial translocation across epithelial cells was assessed, as previously described [41]. MDCK cells (2×10^5 cells) were cultured on polycarbonate Millicell culture plate inserts

(12-mm diameter, 3- μ m pore size; Merck Millipore) at 37°C under 5% CO₂ atmosphere. Transepithelial electrical resistance (TEER) of the filter-grown monolayers was measured using a Millicell-ERS device (Merck Millipore) as an index for integrity of the tight junctions (TJ). Polarized monolayers exhibiting TEER values of 150–300 Ω cm² were used as an *in vitro* model of the epithelial barrier. The monolayers were infected with leptospires at a MOI of 100. The ability of *Leptospira* strains to translocate across the epithelial barrier was assessed by quantifying bacteria in the culture medium recovered from the lower chambers at 1, 2, 4, 6, and 8 h after infection.

Evaluation of virulence in hamster model of infection

The virulence of Manilae WT and the mutant strains (Δ *mpl36* and Δ *mpl36*⁺) was assessed in 3-week male Golden Syrian hamsters, as described previously [41]. Groups of 4 hamsters were infected via intraperitoneal (IP) and ocular conjunctiva (CJ) routes with 10⁸ leptospires. When appropriated, a LD₅₀ experiment was performed using 10⁸, 10⁶ and 10⁴ leptospires by IP route or 10⁸ and 10⁶ by CJ route. Experiments were repeated at least once for reproducibility. Animals were monitored twice daily for signs of disease and death, up to 21-days post-infection. Surviving animals at the end of the experiment or moribund animals showing difficulty in moving, breathing, and/or signs of bleeding or seizure were immediately sacrificed by inhalation of CO₂. Blood, liver, and kidneys were collected from all animals after euthanasia. Kidneys were harvested and DNA was extracted for quantitative real-time PCR (qPCR) targeting *lipL32*, as previously described [41].

Bioinformatic and phylogenetic analysis

Tertiary structure prediction of the SPOR domains from RlpA of *L. interrogans*, *L. fainei* and *L. biflexa* tertiary structure prediction was determined by AlphaFold [58], and PyMOL software (version 2.5.4) was used for analysis. Sequences of MPL36 SPOR domain of *L. interrogans* and from 69 different species of *Leptospira* spp., representing pathogenic (P1 and P2) or saprophytes (S1, S2) bacteria, were obtained and aligned by ClustalX software (version 2.1). Phylogenetic tree was built with ClustalW software (version 2.1).

Statistical analysis

Prism 9 (GraphPad Software) was employed for all the statistical analysis of *in vivo* data. Fisher's exact test and analysis of variance (ANOVA) with Bonferroni's multiple comparisons post-tests were applied to assess statistical differences between pairs of groups and multiple groups, respectively. Experiments for degradation of ECM substrates and C3b were carried out with three or four replicates. Data were presented as mean \pm SD or SEM as shown in the figures. All data were assessed by SPSS 11.5 Software. A *P* value of <0.05 was considered significant.

Supporting information

S1 Fig. Development and characterization of MPL36 mutants. (A) Schematic representation of HimarI transposon insertion positions in *L. interrogans* Manilae L495. The insertion sites of the transposon in the chromosome of the *mpl36* gene in strain Manilae WT, and the insertion site of the transposon containing the spectinomycin resistance cassette and *mpl36* gene for complementation are indicated. (B) Immunoblot analysis of Manilae WT, mutant Δ *mpl36* and complemented strain Δ *mpl36*⁺ using a rabbit polyclonal antibody against rMPL36. The visible band has a molecular weight of ~40 kDa, which is in accordance with the predicted molecular

weight of MPL36. The mutant strain lacks the expression of the protein. Molecular mass markers are shown on the left. (C) Motility assay results for Manilae WT, $\Delta mpl36$, and $\Delta mpl36^+$ strains at 30°C. Bacteria (10^5 cells) were inoculated on 0.5% agarose EMJH plates (each square, 1 cm²) for 10 days. (D) Growth curve analysis of Manilae WT, $\Delta mpl36$, and $\Delta mpl36^+$ strains at 30°C. Bacteria were grown in EMJH medium without agitation, and the counting was performed using dark field microscopy. Results represent the average \pm the standard deviation of three independent experiments.

(TIFF)

S2 Fig. Surface localization of MPL36 and immunogenicity in humans. (A) Whole intact Manilae WT (WCP) was treated with Triton X-114 for phase partitioning of *Leptospira* membrane proteins. Immuno-blot analysis was conducted with detergent (D) and aqueous (A) phase using polyclonal rabbit antisera against LigA (outer membrane), GroEL (cytoplasmic), and MPL36 proteins. Antibodies to rMPL36 in human sera from individuals with confirmed severe leptospirosis were measured by an ELISA assay. Reactivity of the rMPL36 with acute and convalescent serum samples was tested for IgM (B) and IgG (C) levels separately. The dashed line represents the threshold calculated based on 2.5 SD of the average OD signal of sera from healthy US individuals used as control. Data show the mean absorbance value at 450 nm \pm the standard deviation of all individuals tested.

(TIFF)

S3 Fig. Structural and phylogenetic analysis of MPL36 across species. (A) Tertiary predicted model of the SPOR domain of MPL36 in *L. interrogans*, visualized by PyMOL, showing the exposed lysine residues in blue. (B) Alignment of tertiary predicted structures of SPOR domain from *L. interrogans* (P1-red), *L. fainei* (P2-pink), and *L. biflexa* (S1-green), visualized by PyMOL, showing the exposed lysine residues. (C) Dendrogram resulting from multiple alignments performed by ClustalW of SPOR domain of MPL36 with other similar sequences of all 69 *Leptospira* species separated by groups: P1 (red), P2 (pink), S1 (green), and S2 (blue), identified by BLASTp. (D) Alignment of the SPOR domain of MPL36 with other similar sequences of all 69 *Leptospira* species: P1 (red), P2 (pink), S1 (green), and S2 (blue). Alignment was done using the ClustalX software and similar amino acids have the same colors.

(TIFF)

S4 Fig. Assessment of ECM and complement C3b degradation by PLA bound to *Leptospira* strains. Strains Manilae WT, $\Delta mpl36$, $\Delta mpl36^+$ (10^8 cells) were incubated with purified human PLG (10 μ g). After washing, laminin (5 μ g), vitronectin (2.5 μ g) or C3b (1.5 μ g) plus uPA (3 U) were added and incubated for up to 18 h. Leptospiral supernatants were collected and analyzed by western blot using anti-human vitronectin, laminin, or C3b (1:5,000) followed by peroxidase-conjugated secondary antibodies (1: 10,000).

(TIFF)

S5 Fig. Structural analysis of recombinant rMPL36 protein and relevant constructs. Tryptophan fluorescence emission spectra of rMPL36, rMPL36 aa41-305, rMPL36 aa41-235, and the corresponding unfolded proteins. Fluorescence measurements were carried out on a fluorescence spectrophotometer in a 1 cm path length rectangular quartz cuvette. The intrinsic fluorescence emission of native and unfolded proteins was measured in 10 mM PBS, with excitation at 280 nm and emission recorded in the range of 300–400 nm.

(TIFF)

S1 Table. List of primers used in this study.

(XLSX)

S2 Table. Animal experiments to confirm virulence of Manilae WT, Δ mpl36 and Δ mpl36 + strains using hamster model of acute leptospirosis infected with a dose of 108 leptospire by intraperitoneal (IP) or conjunctival (CJ) routes.

(XLSX)

Acknowledgments

We would like to thank Matilde Costa Lima de Souza and Daniella dos Santos Courrol (Laboratory of Bacteriology, Instituto Butantan, São Paulo, Brazil), and Dr. Karukriti K. Ghosh (Yale School of Public Health, CT, US) for technical assistance. We also wanted to thank Dr. Mathieu Picardeau (Institut Pasteur, Paris, France) for providing the *Himar1* mutant of MPL36 (LIC10054) used in our studies.

Author Contributions

Conceptualization: Weinan Zhu, Albert I. Ko, Elsie A. Wunder, Jr.

Data curation: Weinan Zhu, Felipe J. Passalia, Angela S. Barbosa, Elsie A. Wunder, Jr.

Formal analysis: Weinan Zhu, Felipe J. Passalia, Angela S. Barbosa, Elsie A. Wunder, Jr.

Funding acquisition: Felipe J. Passalia, Camila Hamond, Albert I. Ko, Angela S. Barbosa, Elsie A. Wunder, Jr.

Investigation: Weinan Zhu, Felipe J. Passalia, Camila Hamond, Angela S. Barbosa, Elsie A. Wunder, Jr.

Methodology: Weinan Zhu, Felipe J. Passalia, Camila Hamond, Cecília M. Abe, Albert I. Ko, Angela S. Barbosa, Elsie A. Wunder, Jr.

Project administration: Weinan Zhu, Elsie A. Wunder, Jr.

Resources: Cecília M. Abe, Albert I. Ko, Angela S. Barbosa, Elsie A. Wunder, Jr.

Supervision: Weinan Zhu, Felipe J. Passalia, Elsie A. Wunder, Jr.

Validation: Weinan Zhu, Felipe J. Passalia, Angela S. Barbosa, Elsie A. Wunder, Jr.

Writing – original draft: Weinan Zhu, Felipe J. Passalia, Elsie A. Wunder, Jr.

Writing – review & editing: Weinan Zhu, Felipe J. Passalia, Camila Hamond, Cecília M. Abe, Albert I. Ko, Angela S. Barbosa, Elsie A. Wunder, Jr.

References

1. Lahteenmaki K, Kuusela P, Korhonen TK. Bacterial plasminogen activators and receptors. *FEMS Microbiol Rev.* 2001; 25(5):531–52. <https://doi.org/10.1111/j.1574-6976.2001.tb00590.x> PMID: 11742690.
2. Sanderson-Smith ML, De Oliveira DM, Ranson M, McArthur JD. Bacterial plasminogen receptors: mediators of a multifaceted relationship. *Journal of biomedicine & biotechnology.* 2012; 2012:272148. Epub 20121014. <https://doi.org/10.1155/2012/272148> PMID: 23118502; PubMed Central PMCID: PMC3478875.
3. Barthel D, Schindler S, Zipfel PF. Plasminogen is a complement inhibitor. *The Journal of biological chemistry.* 2012; 287(22):18831–42. Epub 20120327. <https://doi.org/10.1074/jbc.M111.323287> PMID: 22451663; PubMed Central PMCID: PMC3365705.
4. Daroz BB, Fernandes LGV, Cavenague MF, Kochi LT, Passalia FJ, Takahashi MB, et al. A Review on Host-Leptospira Interactions: What We Know and Future Expectations. *Frontiers in cellular and infection microbiology.* 2021; 11:777709. Epub 20211125. <https://doi.org/10.3389/fcimb.2021.777709> PMID: 34900757; PubMed Central PMCID: PMC8657130.

5. Ko AI, Goarant C, Picardeau M. *Leptospira*: the dawn of the molecular genetics era for an emerging zoonotic pathogen. *Nature reviews Microbiology*. 2009; 7(10):736–47. <https://doi.org/10.1038/nrmicro2208> PMID: 19756012; PubMed Central PMCID: PMC3384523.
6. Costa F, Hagan JE, Calcagno J, Kane M, Torgerson P, Martinez-Silveira MS, et al. Global Morbidity and Mortality of Leptospirosis: A Systematic Review. *PLoS neglected tropical diseases*. 2015; 9(9): e0003898. <https://doi.org/10.1371/journal.pntd.0003898> PMID: 26379143; PubMed Central PMCID: PMC4574773.
7. Marotto PC, Nascimento CM, Eluf-Neto J, Marotto MS, Andrade L, Sztajnbock J, et al. Acute lung injury in leptospirosis: clinical and laboratory features, outcome, and factors associated with mortality. *Clinical infectious diseases: an official publication of the Infectious Diseases Society of America*. 1999; 29(6):1561–3. <https://doi.org/10.1086/313501> PMID: 10585813.
8. Marotto PC, Ko AI, Murta-Nascimento C, Seguro AC, Prado RR, Barbosa MC, et al. Early identification of leptospirosis-associated pulmonary hemorrhage syndrome by use of a validated prediction model. *The Journal of infection*. 2010; 60(3):218–23. Epub 2009/12/23. <https://doi.org/10.1016/j.jinf.2009.12.005> PMID: 20026189.
9. Segura ER, Ganoza CA, Campos K, Ricaldi JN, Torres S, Silva H, et al. Clinical spectrum of pulmonary involvement in leptospirosis in a region of endemicity, with quantification of leptospiral burden. *Clinical infectious diseases: an official publication of the Infectious Diseases Society of America*. 2005; 40(3):343–51. Epub 2005/01/26. <https://doi.org/10.1086/427110> PMID: 15668855; PubMed Central PMCID: PMC2366057.
10. Gouveia EL, Metcalfe J, de Carvalho AL, Aires TS, Villasboas-Bisneto JC, Queiroz A, et al. Leptospirosis-associated severe pulmonary hemorrhagic syndrome, Salvador, Brazil. *Emerging infectious diseases*. 2008; 14(3):505–8. <https://doi.org/10.3201/eid1403.071064> PMID: 18325275; PubMed Central PMCID: PMC2570821.
11. Panaphut T, Domrongkitchaiporn S, Thinkamrop B. Prognostic factors of death in leptospirosis: a prospective cohort study in Khon Kaen, Thailand. *International journal of infectious diseases: IJID: official publication of the International Society for Infectious Diseases*. 2002; 6(1):52–9. [https://doi.org/10.1016/s1201-9712\(02\)90137-2](https://doi.org/10.1016/s1201-9712(02)90137-2) PMID: 12044303.
12. Herath N, Uluwattage W, Welivitiya T, Karunanayake L, Lekamwasam S, Ratnatunga N, et al. Sequel and therapeutic modalities of leptospirosis associated severe pulmonary haemorrhagic syndrome (SPHS); a Sri Lankan experience. *BMC infectious diseases*. 2019; 19(1):451. Epub 2019/05/22. <https://doi.org/10.1186/s12879-019-4094-0> PMID: 31113404; PubMed Central PMCID: PMC6530063.
13. Bharti AR, Nally JE, Ricaldi JN, Matthias MA, Diaz MM, Lovett MA, et al. Leptospirosis: a zoonotic disease of global importance. *The Lancet infectious diseases*. 2003; 3(12):757–71. Epub 2003/12/04. [https://doi.org/10.1016/s1473-3099\(03\)00830-2](https://doi.org/10.1016/s1473-3099(03)00830-2) PMID: 14652202.
14. Ko AI, Galvao Reis M, Ribeiro Dourado CM, Johnson WD Jr., Riley LW. Urban epidemic of severe leptospirosis in Brazil. *Salvador Leptospirosis Study Group*. *Lancet*. 1999; 354(9181):820–5. [https://doi.org/10.1016/s0140-6736\(99\)80012-9](https://doi.org/10.1016/s0140-6736(99)80012-9) PMID: 10485724.
15. Vincent AT, Schiettekatte O, Goarant C, Neela VK, Bernet E, Thibeaux R, et al. Revisiting the taxonomy and evolution of pathogenicity of the genus *Leptospira* through the prism of genomics. *PLoS neglected tropical diseases*. 2019; 13(5):e0007270. Epub 2019/05/24. <https://doi.org/10.1371/journal.pntd.0007270> PMID: 31120895; PubMed Central PMCID: PMC6532842.
16. Korba AA, Lounici H, Kainiu M, Vincent AT, Mariet JF, Veyrier FJ, et al. *Leptospira ainahdjerensis* sp. nov., *Leptospira ainazelensis* sp. nov., *Leptospira abararensis* sp. nov. and *Leptospira chreensis* sp. nov., four new species isolated from water sources in Algeria. *International journal of systematic and evolutionary microbiology*. 2021;71(12). Epub 2021/12/17. <https://doi.org/10.1099/ijsem.0.005148> PMID: 34914572.
17. Wunder EA Jr., Figueira CP, Santos GR, Lourdault K, Matthias MA, Vinetz JM, et al. Real-Time PCR Reveals Rapid Dissemination of *Leptospira interrogans* after Intraperitoneal and Conjunctival Inoculation of Hamsters. *Infection and immunity*. 2016; 84(7):2105–15. <https://doi.org/10.1128/IAI.00094-16> PMID: 27141082; PubMed Central PMCID: PMC4936353.
18. Gostic KM, Wunder EA Jr., Bisht V, Hamond C, Julian TR, Ko AI, et al. Mechanistic dose-response modelling of animal challenge data shows that intact skin is a crucial barrier to leptospiral infection. *Philos Trans R Soc Lond B Biol Sci*. 2019; 374(1782):20190367. Epub 2019/08/14. <https://doi.org/10.1098/rstb.2019.0367> PMID: 31401957; PubMed Central PMCID: PMC6711307.
19. Tahara H, Takabe K, Sasaki Y, Kasuga K, Kawamoto A, Koizumi N, et al. The mechanism of two-phase motility in the spirochete *Leptospira*: Swimming and crawling. *Sci Adv*. 2018; 4(5):eaar7975. Epub 2018/05/30. <https://doi.org/10.1126/sciadv.aar7975> PMID: 29854948; PubMed Central PMCID: PMC5976277.

20. Charon NW, Cockburn A, Li C, Liu J, Miller KA, Miller MR, et al. The unique paradigm of spirochete motility and chemotaxis. *Annu Rev Microbiol.* 2012; 66:349–70. Epub 2012/09/22. <https://doi.org/10.1146/annurev-micro-092611-150145> PMID: 22994496.
21. Coburn J, Picardeau M, Woods CW, Veldman T, Haake DA. Pathogenesis insights from an ancient and ubiquitous spirochete. *PLoS pathogens.* 2021; 17(10):e1009836. Epub 20211021. <https://doi.org/10.1371/journal.ppat.1009836> PMID: 34673833; PubMed Central PMCID: PMC8530280.
22. Vieira ML, Fernandes LG, Domingos RF, Oliveira R, Siqueira GH, Souza NM, et al. Leptospiral extracellular matrix adhesins as mediators of pathogen-host interactions. *FEMS microbiology letters.* 2014; 352(2):129–39. <https://doi.org/10.1111/1574-6968.12349> PMID: 24289724.
23. Figueira CP, Croda J, Choy HA, Haake DA, Reis MG, Ko AI, et al. Heterologous expression of pathogen-specific genes *ligA* and *ligB* in the saprophyte *Leptospira biflexa* confers enhanced adhesion to cultured cells and fibronectin. *BMC microbiology.* 2011; 11:129. <https://doi.org/10.1186/1471-2180-11-129> PMID: 21658265; PubMed Central PMCID: PMC3133549.
24. Robbins GT, Hahn BL, Evangelista KV, Padmore L, Aranda PS, Coburn J. Evaluation of cell binding activities of *Leptospira* ECM adhesins. *PLoS neglected tropical diseases.* 2015; 9(4):e0003712. Epub 20150414. <https://doi.org/10.1371/journal.pntd.0003712> PMID: 25875373; PubMed Central PMCID: PMC4397020.
25. da Silva LB, Menezes MC, Kitano ES, Oliveira AK, Abreu AG, Souza GO, et al. *Leptospira interrogans* Secreted Proteases Degrade Extracellular Matrix and Plasma Proteins From the Host. *Frontiers in cellular and infection microbiology.* 2018; 8:92. Epub 2018/04/11. <https://doi.org/10.3389/fcimb.2018.00092> PMID: 29637048; PubMed Central PMCID: PMC5881292.
26. Verma A, Brissette CA, Bowman AA, Shah ST, Zipfel PF, Stevenson B. Leptospiral endostatin-like protein A is a bacterial cell surface receptor for human plasminogen. *Infection and immunity.* 2010; 78(5):2053–9. Epub 2010/02/18. <https://doi.org/10.1128/IAI.01282-09> PMID: 20160016; PubMed Central PMCID: PMC2863546.
27. Vieira ML, Vasconcellos SA, Goncalves AP, de Moraes ZM, Nascimento AL. Plasminogen acquisition and activation at the surface of leptospira species lead to fibronectin degradation. *Infection and immunity.* 2009; 77(9):4092–101. <https://doi.org/10.1128/IAI.00353-09> PMID: 19581392; PubMed Central PMCID: PMC2738053.
28. Vieira ML, Atzingen MV, Oliveira TR, Oliveira R, Andrade DM, Vasconcellos SA, et al. In vitro identification of novel plasminogen-binding receptors of the pathogen *Leptospira interrogans*. *PLoS one.* 2010; 5(6):e11259. <https://doi.org/10.1371/journal.pone.0011259> PMID: 20582320; PubMed Central PMCID: PMC2889836.
29. Castiblanco-Valencia MM, Fraga TR, Pagotto AH, Serrano SM, Abreu PA, Barbosa AS, et al. Plasmin cleaves fibrinogen and the human complement proteins C3b and C5 in the presence of *Leptospira interrogans* proteins: A new role of *LigA* and *LigB* in invasion and complement immune evasion. *Immunobiology.* 2016; 221(5):679–89. Epub 2016/01/30. <https://doi.org/10.1016/j.imbio.2016.01.001> PMID: 26822552.
30. Wolff DG, Castiblanco-Valencia MM, Abe CM, Monaris D, Moraes ZM, Souza GO, et al. Interaction of *Leptospira* elongation factor Tu with plasminogen and complement factor H: a metabolic leptospiral protein with moonlighting activities. *PLoS one.* 2013; 8(11):e81818. Epub 20131127. <https://doi.org/10.1371/journal.pone.0081818> PMID: 24312361; PubMed Central PMCID: PMC3842364.
31. Salazar N, Souza MC, Biasioli AG, Silva LB, Barbosa AS. The multifaceted roles of *Leptospira* enolase. *Research in microbiology.* 2017; 168(2):157–64. Epub 20161029. <https://doi.org/10.1016/j.resmic.2016.10.005> PMID: 27989763.
32. Vieira ML, Atzingen MV, Oliveira R, Mendes RS, Domingos RF, Vasconcellos SA, et al. Plasminogen binding proteins and plasmin generation on the surface of *Leptospira* spp.: the contribution to the bacteria-host interactions. *Journal of biomedicine & biotechnology.* 2012; 2012:758513. <https://doi.org/10.1155/2012/758513> PMID: 23118516; PubMed Central PMCID: PMC3481863.
33. Arends SJ, Williams K, Scott RJ, Rolong S, Popham DL, Weiss DS. Discovery and characterization of three new *Escherichia coli* septal ring proteins that contain a SPOR domain: DamX, DedD, and RlpA. *Journal of bacteriology.* 2010; 192(1):242–55. <https://doi.org/10.1128/JB.01244-09> PMID: 19880599; PubMed Central PMCID: PMC2798263.
34. Gerding MA, Liu B, Bendezu FO, Hale CA, Bernhardt TG, de Boer PA. Self-enhanced accumulation of FtsN at Division Sites and Roles for Other Proteins with a SPOR domain (DamX, DedD, and RlpA) in *Escherichia coli* cell constriction. *Journal of bacteriology.* 2009; 191(24):7383–401. Epub 20090814. <https://doi.org/10.1128/JB.00811-09> PMID: 19684127; PubMed Central PMCID: PMC2786604.
35. Yahashiri A, Jorgenson MA, Weiss DS. The SPOR Domain, a Widely Conserved Peptidoglycan Binding Domain That Targets Proteins to the Site of Cell Division. *Journal of bacteriology.* 2017; 199(14). Epub 20170627. <https://doi.org/10.1128/JB.00118-17> PMID: 28396350; PubMed Central PMCID: PMC5494741.

36. Alcorlo M, Dik DA, De Benedetti S, Mahasenan KV, Lee M, Dominguez-Gil T, et al. Structural basis of denuded glycan recognition by SPOR domains in bacterial cell division. *Nat Commun.* 2019; 10(1):5567. Epub 20191205. <https://doi.org/10.1038/s41467-019-13354-4> PMID: 31804467; PubMed Central PMCID: PMC6895207.
37. Jorgenson MA, Chen Y, Yahashiri A, Popham DL, Weiss DS. The bacterial septal ring protein RlpA is a lytic transglycosylase that contributes to rod shape and daughter cell separation in *Pseudomonas aeruginosa*. *Molecular microbiology.* 2014; 93(1):113–28. Epub 20140523. <https://doi.org/10.1111/mmi.12643> PMID: 24806796; PubMed Central PMCID: PMC4086221.
38. Murray GL, Morel V, Cerqueira GM, Croda J, Srikram A, Henry R, et al. Genome-wide transposon mutagenesis in pathogenic *Leptospira* species. *Infection and immunity.* 2009; 77(2):810–6. <https://doi.org/10.1128/IAI.01293-08> PMID: 19047402; PubMed Central PMCID: PMC2632054.
39. Barbosa AS, Monaris D, Silva LB, Morais ZM, Vasconcellos SA, Cianciarullo AM, et al. Functional characterization of LcpA, a surface-exposed protein of *Leptospira* spp. that binds the human complement regulator C4BP. *Infection and immunity.* 2010; 78(7):3207–16. <https://doi.org/10.1128/IAI.00279-10> PMID: 20404075; PubMed Central PMCID: PMC2897400.
40. Gamberini M, Gomez RM, Atzingen MV, Martins EA, Vasconcellos SA, Romero EC, et al. Whole-genome analysis of *Leptospira interrogans* to identify potential vaccine candidates against leptospirosis. *FEMS microbiology letters.* 2005; 244(2):305–13. <https://doi.org/10.1016/j.femsle.2005.02.004> PMID: 15766783.
41. Wunder EA Jr., Figueira CP, Benaroudj N, Hu B, Tong BA, Trajtenberg F, et al. A novel flagellar sheath protein, FcpA, determines filament coiling, translational motility and virulence for the *Leptospira* spirochete. *Molecular microbiology.* 2016; 101(3):457–70. <https://doi.org/10.1111/mmi.13403> PMID: 27113476; PubMed Central PMCID: PMC4979076.
42. Oliveira R, Domingos RF, Siqueira GH, Fernandes LG, Souza NM, Vieira ML, et al. Adhesins of *Leptospira interrogans* mediate the interaction to fibrinogen and inhibit fibrin clot formation in vitro. *PLoS neglected tropical diseases.* 2013; 7(8):e2396. Epub 20130829. <https://doi.org/10.1371/journal.pntd.0002396> PMID: 24009788; PubMed Central PMCID: PMC3757074.
43. Hartwig DD, Seixas FK, Cerqueira GM, McBride AJ, Dellagostin OA. Characterization of the immunogenic and antigenic potential of putative lipoproteins from *Leptospira interrogans*. *Current microbiology.* 2011; 62(4):1337–41. <https://doi.org/10.1007/s00284-010-9865-1> PMID: 21221970.
44. Ono E, Takase H, Naiki M, Yanagawa R. Purification, characterization and serological properties of a glycolipid antigen reactive with a serovar-specific monoclonal antibody against *Leptospira interrogans* serovar canicola. *Journal of general microbiology.* 1987; 133(5):1329–36. Epub 1987/05/01. <https://doi.org/10.1099/00221287-133-5-1329> PMID: 3655741.
45. Caimano MJ, Sivasankaran SK, Allard A, Hurley D, Hokamp K, Grassmann AA, et al. A model system for studying the transcriptomic and physiological changes associated with mammalian host-adaptation by *Leptospira interrogans* serovar Copenhageni. *PLoS pathogens.* 2014; 10(3):e1004004. <https://doi.org/10.1371/journal.ppat.1004004> PMID: 24626166; PubMed Central PMCID: PMC3953431.
46. Adhikarla H, Wunder EA Jr., Mechaly AE, Mehta S, Wang Z, Santos L, et al. Lvr, a Signaling System That Controls Global Gene Regulation and Virulence in Pathogenic *Leptospira*. *Frontiers in cellular and infection microbiology.* 2018; 8:45. Epub 2018/03/31. <https://doi.org/10.3389/fcimb.2018.00045> PMID: 29600195; PubMed Central PMCID: PMC5863495.
47. Wunder EA, Adhikarla H, Hamond C, Owers Bonner KA, Liang L, Rodrigues CB, et al. A live attenuated-vaccine model confers cross-protective immunity against different species of the *Leptospira* genus. *Elife.* 2021;10. Epub 2021/01/27. <https://doi.org/10.7554/eLife.64166> PMID: 33496263; PubMed Central PMCID: PMC7837694.
48. Pazos M, Peters K, Boes A, Safaei Y, Kenward C, Caveney NA, et al. SPOR Proteins Are Required for Functionality of Class A Penicillin-Binding Proteins in *Escherichia coli*. *mBio.* 2020; 11(6). Epub 20201103. <https://doi.org/10.1128/mBio.02796-20> PMID: 33144379; PubMed Central PMCID: PMC7642682.
49. Passalia FJ, Heinemann MB, de Andrade SA, Nascimento A, Vieira ML. *Leptospira interrogans* Bat proteins impair host hemostasis by fibrinogen cleavage and platelet aggregation inhibition. *Medical microbiology and immunology.* 2020; 209(2):201–13. Epub 20200220. <https://doi.org/10.1007/s00430-020-00664-4> PMID: 32078713.
50. Sumitomo T, Nakata M, Higashino M, Yamaguchi M, Kawabata S. Group A *Streptococcus* exploits human plasminogen for bacterial translocation across epithelial barrier via tricellular tight junctions. *Sci Rep.* 2016; 7:20069. Epub 20160129. <https://doi.org/10.1038/srep20069> PMID: 26822058; PubMed Central PMCID: PMC4731814.
51. Fulde M, Rohde M, Polok A, Preissner KT, Chhatwal GS, Bergmann S. Cooperative plasminogen recruitment to the surface of *Streptococcus canis* via M protein and enolase enhances bacterial

- survival. *mBio*. 2013; 4(2):e00629–12. Epub 20130312. <https://doi.org/10.1128/mBio.00629-12> PMID: 23481605; PubMed Central PMCID: PMC3604778.
52. Law RH, Caradoc-Davies T, Cowieson N, Horvath AJ, Quek AJ, Encarnacao JA, et al. The X-ray crystal structure of full-length human plasminogen. *Cell Rep*. 2012; 1(3):185–90. Epub 20120308. <https://doi.org/10.1016/j.celrep.2012.02.012> PMID: 22832192.
 53. Johnson RC, Harris VG. Differentiation of pathogenic and saprophytic leptospires. I. Growth at low temperatures. *Journal of bacteriology*. 1967; 94(1):27–31. <https://doi.org/10.1128/jb.94.1.27-31.1967> PMID: 6027998; PubMed Central PMCID: PMC251866.
 54. Haake DA, Matsunaga J. Characterization of the leptospiral outer membrane and description of three novel leptospiral membrane proteins. *Infection and immunity*. 2002; 70(9):4936–45. Epub 2002/08/17. <https://doi.org/10.1128/IAI.70.9.4936-4945.2002> PMID: 12183539; PubMed Central PMCID: PMC128291.
 55. Ramos CR, Abreu PA, Nascimento AL, Ho PL. A high-copy T7 Escherichia coli expression vector for the production of recombinant proteins with a minimal N-terminal His-tagged fusion peptide. *Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas / Sociedade Brasileira de Biofisica [et al]*. 2004; 37(8):1103–9. Epub 20040720. <https://doi.org/10.1590/s0100-879x2004000800001> PMID: 15273812.
 56. Ghisaidoobe AB, Chung SJ. Intrinsic tryptophan fluorescence in the detection and analysis of proteins: a focus on Forster resonance energy transfer techniques. *Int J Mol Sci*. 2014; 15(12):22518–38. Epub 20141205. <https://doi.org/10.3390/ijms151222518> PMID: 25490136; PubMed Central PMCID: PMC4284722.
 57. Picardeau M. Toolbox of Molecular Techniques for Studying Leptospira Spp. *Current topics in microbiology and immunology*. 2018; 415:141–62. https://doi.org/10.1007/82_2017_45 PMID: 28849314.
 58. Jumper J, Evans R, Pritzel A, Green T, Figurnov M, Ronneberger O, et al. Highly accurate protein structure prediction with AlphaFold. *Nature*. 2021; 596(7873):583–9. Epub 20210715. <https://doi.org/10.1038/s41586-021-03819-2> PMID: 34265844; PubMed Central PMCID: PMC8371605.